June 4, 2026
Hassan Mohammed Abushukair MD; AACR 2026: Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
Immune Checkpoint Inhibitor-Induced Myocarditis within One Month Predicts Lethal “Triple M Overlap Syndrome”
An interview with:
Hassan Mohammed Abushukair MD, Post-Doctoral Researcher, Oklahoma University Stephenson Cancer Center, Oklahoma City
SAN DIEGO, USA—A frequently fatal side effect of immune checkpoint inhibition known as the “Triple M Overlap Syndrome” can be predicted if myocarditis is noted in the first month of immunotherapy. That’s according to researchers who reported study findings at the 2026 Annual Meeting of the American Association for Cancer Research.
First author Hassan Abushukair MD, a Post-Doctoral Researcher at Oklahoma University Stephenson Cancer Center in Oklahoma City gave the details to Peter Goodwin.
AUDIO JOURNAL OF ONCOLOGY; Hassan Mohammed Abushukair MD
IN: [GOODWIN]”We are at……..
OUT: ……I’m Peter Goodwin” 10:44secs
STUDY CONCLUSION:
“This is the largest global dataset to characterize TMOS and MC fatality. Our data shows that TMOS represents a uniquely fatal phenotype of ICI-MC with a higher tendency in cancers with wider ICI use. Regarding MC fatality, we show MC timing to be a critical determinant of fatality, specifically within the first month of ICI start, demonstrating the need for refined screening and monitoring strategies within this time window”
AACR 2026 Abstract 5212
Title:
Clinical characterization of immune checkpoint inhibitor-induced myocarditis and the triple M overlap syndrome
Authors:
Hassan Mohammed Abushukair1, Eman Alghamdi2, Woncheol Jung1, Mehak Laharwal3, Hafsa Gundroo4, Sagal Pannu5, Aik Choon Tan6, Pauline Funchain7, NohaAbdel-Wahab8, Elad Sharon9, Douglas B. Johnson10, Amin H. Nassar11, Fawaz Al-Harbi2, Tae Gyu Oh1, Abdul Rafeh Naqash5
1Oncology Science, University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK,
2Saudi Food and Drug Authority, Riyadh, Saudi Arabia,
3Allegheny Health Network Cancer Institute, Pittsburgh, PA,
4Morehouse School of Medicine, Atlanta, GA,
5University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK,
6Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT,
7Stanford Cancer Institute, Pao Alto, CA,
8The University of Texas MD Anderson Cancer Center, Houston, TX,
9Dana-Farber Cancer Institute, Boston, MA,
10Vanderbilt Ingram Cancer Center, Nashville, TN,
11Yale University, New Haven, CT
Background:
Immune checkpoint inhibitor (ICI)-induced myocarditis (MC) is one of the most fatal immune-related adverse events (irAEs) in cancer patients, often overlapping with myositis (MS) and myasthenia gravis (MG), forming the fulminant triad of Triple M Overlap Syndrome (TMOS). In this study, we report the largest clinical series of this rare fatal syndrome, aimed at delineating clinical features, fatality predictors, and temporal trends.
Methods:
We surveyed the WHO Vigibase pharmacovigilance database for cases of ICI- MC, MS, and MG in cancer cases through January 1, 2025. Seven groups emerged: MC alone, MS alone, MG alone, MC+MS, MC+MG, MS+MG, and TMOS. A machine learning (ML) model using the XGBoost algorithm was constructed using a subset (n = 858) of ICI- MC with complete data availability (age, sex, co-reactions, cancer/ICI type, and MC timing) for MC fatality prediction with an 80/20% data split for training and internal testing. An external public real-world dataset (n = 28) of ICI-MC was used for independent validation of our fatality ML prediction model.
Results:
Among a total of 4,950 ICI-MC/MS/MG cases, we identified 2,641 ICI-MC cases, of which 1,911 (72.4%) were MC alone and 730 (27.6%) were overlapping with MS and/or MG (MC+MS = 364, 13.8%; MC+MG = 159, 6%; TMOS = 207, 7.8%). TMOS occurred predominantly in melanoma (35.8%) and was more likely in males (64.7% vs 52.9%, p- value = 0.0049) treated with ICI dual therapy (25.1% vs 20.4%, p-value = 0.0030) compared with MC alone. Hepatitis was the most common irAE co-occurring in cases with TMOS (n = 30, 14.5%). MC-specific fatality rates were higher in TM
